CABA-201
Asset
Autologous CD19-directed CAR T cells deplete B cells to reduce autoimmune activity.
- Stage
- Phase 1
- Modality
- Cell therapy
- Target
- CD19
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Generalized myasthenia gravis
Phase 1, Recruiting, NCT06359041, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors5
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.